Big Tobacco Built a Nicotine Tablet That Looks Like a Breath Mint. Ask Who It's For Before It Lands Here.
Zyn Melts and Perlz launched in the U.K. without any approval process. For a smoker trying to quit, a lower-risk nicotine product can help. For a 14-year-old, a mint is a mint.
Philip Morris International’s newest product is a small mint-flavored tablet that dissolves on your tongue. It is called Zyn Melts, it comes in 1 mg and 2 mg, and since this fall it has been on sale in the U.K. and Switzerland, where nobody had to approve it first. Japan Tobacco’s version, Perlz, launched in the U.K. in May. PMI has already filed U.S. trademarks for Zyn Melts, both as a consumer product and as a quit-smoking aid.
A nicotine product that helps a smoker quit cigarettes is harm reduction. The same product shaped like candy and sold without review is a recruitment tool.
Both of those sentences can be true at once, which is why the review matters. Nicotine is what keeps people hooked, but burning tobacco is the most harmful way to get it, the FDA’s own education page says; the smoke carries the disease. For an adult who has failed to quit cigarettes five times, switching to a product without combustion is a real step toward living longer, and the FDA has said as much in a narrow way. When it authorized 20 Zyn pouch products in January 2025, the agency also stressed that authorization does not mean the products are safe or “FDA approved,” and that it could pull them if young people started using them.
Young people already are. In 2024, 1.8% of U.S. middle and high school students, about 480,000 kids, had used nicotine pouches in the past month, according to the CDC’s national youth survey. The Examination reports that U.S. poison control calls involving nicotine, many of them pouches, nearly doubled from 2024 to 2025, and three-quarters of last year’s cases involved children under 6. A tablet that looks like a mint makes the toddler problem worse in a way a pouch never did. Karolinska Institutet cardiologist Magnus Lundbäck told The Examination the format “may make them appear harmless and more appealing to children and adolescents.” Former FDA tobacco chief Mitch Zeller said the tablets “could possibly be helpful” to smokers in a properly regulated market, and that the consequences “need to be sorted out on a pre-market basis.”
That pre-market review is the gate. In the U.S., a nicotine tablet sold to consumers rather than as a quit aid needs its own FDA review. Zeller warned that a newer FDA policy allowing products to sell while their applications are pending could put tablets on shelves before anyone studies their appeal to teenagers.
If you are trying to quit smoking and a pouch or a tablet is the thing that finally keeps you off cigarettes, that is a real win, and nobody should shame you for it. Our spotlight on why the next cigarette follows the bad hour is about what’s actually driving the craving. For pediatric and family providers, add nicotine tablets and pouches by name to youth screening questions this month, and tell parents to store them like medicine, not like mints.
The test for any of these products is simple: does it move a smoker away from cigarettes, or a kid toward nicotine? A tablet built to look like candy has already told you which one its designers were thinking about.
Sources Cited
- 01.B
- 02.A
- 03.ANicotine Is Why Tobacco Products Are AddictiveFDA Center for Tobacco Products
- 04.A
Filed Under
harm-reductionpolicytrendsNicotineFDAYouth & Young AdultsIndustry / Trade
Keep up with the reporting.
One email each morning with the stories that put days like this in context.
Continue reading
More from this section
45 Days Out, the Rules for Telehealth Prescriptions Are Still in a Document Nobody Can Read
The DEA's telemedicine prescribing flexibilities end Dec. 31, 2026, and the special registration rule is still unpublished. What happens to buprenorphine, ADHD and other telehealth prescriptions, and what to do this week.
Technology & InnovationTelehealth Is Selling GLP-1s for Alcohol Use. The FDA Hasn't Said Yes, and the Patient Is Holding the Risk.
Online addiction platforms are prescribing GLP-1 drugs off-label for alcohol use disorder ahead of any FDA approval, shifting the burden of vetting to patients.
Technology & InnovationTelehealth Is Selling GLP-1s for Addiction Before the FDA Has Said Whether They Work
Online addiction clinics are prescribing GLP-1 drugs off-label for alcohol use disorder ahead of FDA approval. What the early trial data show and what to ask before you start.